ClinicalTrials.gg
RecruitingNCT06670079Updated May 13, 2026

Prolonged Exposure Therapy to Treat Posttraumatic Stress Disorder in Pregnant Patients

An interventional study of Prolonged exposure therapy + incentives for therapy session attendance in Posttraumatic Stress Disorder and Pregnancy, sponsored by University of Vermont. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by University of Vermont · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this clinical trial is to learn if a treatment for adults with PTSD called prolonged exposure + incentives (PE+) works to treat pregnant patients. The main question it aims to answer is:

Does PE+ decrease PTSD symptoms?

All participants will receive PE+ to see if their PTSD symptoms at the end of the trial are less than at the beginning.

Participants will:

  • Receive individual PE+ therapy for 1 hour weekly for 12 weeks.
  • Receive financial incentives for attending each PE+ session.
  • Attend assessment visits every 4 weeks for the 12 weeks of the trial.
  • Allow research staff to collect some information about their labor and delivery from their medical records after their babies are born.
02

Conditions studied

  • Posttraumatic Stress Disorder
  • Pregnancy
03

In context

Stress Disorders, Post-Traumatic

2,682 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 601 are open to participants now.

This study's planned enrollment of 30 is below the median of 69 across 2,196 interventional studies indexed under Stress Disorders, Post-Traumatic.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

University of Vermont is the lead sponsor of 221 studies on the registry; 27 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • >18 years old
  • Gestational age ≤ 25 weeks
  • Meet current posttraumatic stress disorder criteria based on the Clinician Administered PTSD Scale for DSM-5
  • Participants receiving psychotropic medications must be maintained on a stable dose for >14 days prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Male
  • Under 18 years old
  • Gestational age > 25 weeks
  • No current diagnosis of PTSD
  • Current delusions or hallucinations, unstable bipolar disorder, imminent risk for suicide as assessed by the Mini International Neuropsychiatric Interview
  • Enrolled in another ongoing evidence-based treatment for PTSD.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Prolonged exposure therapy + incentives for therapy session attendance

    Behavioral: Prolonged exposure therapy + incentives for therapy session attendance

Interventions

  • BehavioralProlonged exposure therapy + incentives for therapy session attendance

    Prolonged exposure therapy plus incentives for therapy session attendance

06

What researchers measure

Primary outcomes

  1. Change in Posttraumatic Stress Disorder Symptom Severity - Clinician Rated

    Change in posttraumatic stress disorder symptom severity as measured by Clinician Administered PTSD Scale (CAPS-5) for clinician-rated posttraumatic stress symptoms. The CAPS-5 is a 30-item structured interview. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 PTSD symptoms, each with severity scores ranging from 0-4. The overall total severity score for CAPS-5 ranges from 0-80, with lower scores representing better outcomes (less severe PTSD).

    Time frame: From baseline to the 12-week assessment

  2. Acceptability of prolonged exposure therapy + incentives for therapy session attendance

    Change in treatment acceptability as measured by the Treatment Acceptability/Adherence Scale (TAAS). The TAAS is a 10-item scale, each with a range of 1-7 and some of which are reverse-scored. The total TAAS score is calculated by summing the score for the 10 TAAS items and the overall TAAS score ranges from 10-70, with higher scores representing better outcomes (greater treatment acceptability).

    Time frame: From baseline to the 12-week assessment

Secondary outcomes

  1. Change in posttraumatic stress disorder symptom severity - self-reported

    Change in posttraumatic stress disorder symptom severity as measured by PTSD Checklist for DSM-5 (PCL-5) for self-reported posttraumatic stress symptoms. The PCL-5 is a 20-item self-report measure that assesses the 20 symptoms of PTSD. The rating scale is 0-4 for each symptom/item, and overall scores range from 0-80, with lower scores representing better outcomes (less severe PTSD).

    Time frame: From baseline to the 12-week assessment

  2. Mean change in subjective units of distress

    The mean change in subjective units of distress scale (SUDS) ratings from before each imaginal exposure exercise to the peak (highest) level of distress reported during the exercise measured with a single item (range: 0-100).

    Time frame: Within 1-hour

  3. Mean percent change in heart rate

    The mean percent change in heart rate from before each imaginal exposure exercise to peak (highest) heart rate during the exercise

    Time frame: Within 1-hour

  4. Change in self-reported posttraumatic stress disorder symptom severity between PE sessions

    The percentage of participants who have a reliable exacerbation in PTSD symptoms between sessions

    Time frame: In the 1 week

  5. Prolonged exposure therapy discontinuation

    The percentage of participants who complete \<8 prolonged exposure therapy sessions

    Time frame: From baseline to the 12-week assessment

  6. Neonatal birth weight

    Neonatal birth weight in grams

    Time frame: Delivery

  7. Gestational age at delivery

    Gestational age at delivery in weeks

    Time frame: Delivery

  8. Maternal delivery complications

    The percentage of participants who experience delivery complications (i.e., abruption/bleeding, hypertensive disorders, and preterm premature rupture of membranes or preterm labor)

    Time frame: Delivery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06670079
Responsible party
Kelly Peck (Professor, University of Vermont) — Principal investigator
First posted
Nov 1, 2024
Start date
Feb 5, 2026
Primary completion
Jul 15, 2027 (estimated)
Completion
Jul 22, 2027 (estimated)
Last update
May 13, 2026

Study contacts

Kelly Peck, PhD
Contact
kelly.peck@uvm.edu
802-656-9610

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion